Tag: Accelerated Approval
-
Bristol Myers Squibb (BMS) Wins FDA Approval for the First CELMoD Therapy in Multiple Myeloma
The FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) as part of a three-drug regimen for previously treated multiple myeloma, marking the first approval of a CELMoD therapy.
-
Jazz to Withdraw Zepzelca’s Second-Line SCLC Indication After Phase 3 Failure
Jazz plans to withdraw Zepzelca’s second-line small cell lung cancer indication after the Phase 3 LAGOON trial failed to confirm an overall survival benefit.